NCT00536653View on ClinicalTrials.gov

Changes in Bone Mineral Density and Fracture Risk in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer

NACompletedINTERVENTIONAL
Enrollment

618

Participants

Timeline

Start Date

October 31, 1999

Study Completion Date

January 31, 2007

Conditions
Osteoporosis
Interventions
DRUG

Bicalutamide and Calcium/ Vitamin D supplementation

Bicalutamide 150mg once daily, Calcium and Vitamin D supplementation once daily

DRUG

LHRH agonists (Goserelin acetate) and Calcium/ Vitamin D supplementation

3 monthly depot injection of LHRH agonist (Goserelin acetate 10.8mg) and Calcium/ Vitamin D supplementation daily

DRUG

LHRH agonists (Goserelin acetate)

3 monthly depot injection of LHRH agonists (Goserelin acetate 10.8mg)

Trial Locations (1)

CH48 5PE

Wirral University Hospitals NHS Trust, Upton, Wirral

All Listed Sponsors
lead

Wirral University Teaching Hospital NHS Trust

OTHER

NCT00536653 - Changes in Bone Mineral Density and Fracture Risk in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer | Biotech Hunter | Biotech Hunter